Shin 2021.

Study name
Methods	Interventional, parallel group, open label, randomised controlled trial
Participants	Adults aged 19–79 years
Interventions	Prostaglandin (alprostadil) for 2 or 3 weeks
Outcomes	Primary outcome Concentrations of total bilirubin, alanine transaminase, aspartate transaminase, and alkaline phosphatase at 1 year after ABO blood type unsuitable living liver transplant. Safety evaluated by observing bleeding or hepatic arterial thrombosis that occurred during the administration period of the clinical trial drug after ABO blood type incompatible living liver transplant. Also evaluated safety through laboratory tests, measurement of vital signs, and observation of adverse reactions. To compare the frequency of antibody‐mediated rejection (multiple hepatic biliary stenosis) within 1 year after administration of the investigational drug after administration of the investigational drug in patients with ABO blood type incompatible in vivo liver transplantation. Secondary outcome 1‐year graft survival rate after ABO blood type incompatible living liver transplant Participants 1 year after ABO blood type incompatible living liver transplant
Starting date	1 May 2021
Contact information	88 Olympic‐Ro 43‐Gil, Songpa‐Gu, Seoul 05505, Korea Telephone: +82‐2‐3010‐7182 Email: asancrc0516@hanmail.net Affiliation: Asan Medical Center
Notes	CRIS KCT0006115